Total Funding
86
49
Total FundingSeries B raised
Growth Score
-10 pts
Heat Score
-35 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
29493
Kainova Therapeutics develops therapies that modulate GPCRs for the treatment of immuno-oncology and inflammation.
- Sean MacDonald: CEOPast Role: Kainova Therapeutics, Chief Business Officer
- Xavier Leroy: Chief Technology Officer
About the Company
Kainova Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies that modulate GPCRs (G protein-coupled receptors) for the treatment of immuno-oncology and inflammation. The company focuses on small molecules and related modalities that modulate specific biological mechanisms involved in human disease. Its
activities typically include target identification, compound screening, assay development, and preclinical evaluation to assess biological activity and selectivity. The organization collaborates with research partners to support discovery programs and translate early findings into candidate compounds suitable for further development.
